Pharma

Your Article Summary

See Latest Articles

Boston Scientific PROMUS and First-Generation TAXUS Express Stents Continue Excellent Performance in SPIRIT III Trial
Boston Scientific, 09/22/09

Boston Scientific Corporation welcomed three–year results from the SPIRIT III clinical trial, which continue to reaffirm the proven long–term safety of the Company's portfolio of drug–eluting stents, including the first–generation TAXUS Express(2)™ Paclitaxel–Eluting Coronary Stent System and the XIENCE V™ Everolimus–Eluting Coronary Stent System.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09

Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09

 See all of Drug Trials